Zacks Research Weighs in on Novartis AG’s Q3 2026 Earnings (NYSE:NVS)

Novartis AG (NYSE:NVS) – Stock analysts at Zacks Research lowered their Q3 2026 earnings estimates for Novartis in a research report issued on Monday, September 30th. Zacks Research analyst E. Bagri now forecasts that the company will post earnings per share of $2.37 for the quarter, down from their previous forecast of $2.38. The consensus estimate for Novartis’ current full-year earnings is $7.50 per share. Zacks Research also issued estimates for Novartis’ FY2026 earnings at $8.94 EPS.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Thursday, July 18th. The company reported $1.97 EPS for the quarter, beating the consensus estimate of $1.87 by $0.10. Novartis had a net margin of 33.76% and a return on equity of 34.56%. The business had revenue of $12.87 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter last year, the firm posted $1.83 earnings per share.

Other analysts have also recently issued research reports about the stock. Bank of America cut shares of Novartis from a “buy” rating to a “neutral” rating and reduced their target price for the company from $135.00 to $130.00 in a report on Wednesday, September 11th. Jefferies Financial Group cut shares of Novartis from a “buy” rating to a “hold” rating in a report on Tuesday, September 3rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Novartis in a report on Friday, July 19th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $121.00 target price (up previously from $119.00) on shares of Novartis in a report on Thursday, September 5th. Finally, Barclays raised shares of Novartis to a “strong sell” rating in a report on Monday, June 24th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $120.70.

Novartis Trading Up 0.1 %

NYSE NVS opened at $113.93 on Thursday. The firm has a 50 day simple moving average of $115.43 and a 200-day simple moving average of $106.53. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.72 and a current ratio of 0.93. Novartis has a one year low of $92.19 and a one year high of $120.92. The firm has a market cap of $232.87 billion, a price-to-earnings ratio of 15.38, a PEG ratio of 1.73 and a beta of 0.57.

Hedge Funds Weigh In On Novartis

A number of hedge funds have recently modified their holdings of NVS. Private Ocean LLC purchased a new position in shares of Novartis during the first quarter worth approximately $25,000. Richardson Financial Services Inc. purchased a new position in shares of Novartis during the fourth quarter worth approximately $26,000. Clearstead Trust LLC grew its position in shares of Novartis by 73.5% during the first quarter. Clearstead Trust LLC now owns 269 shares of the company’s stock worth $26,000 after acquiring an additional 114 shares during the last quarter. New Millennium Group LLC purchased a new position in shares of Novartis during the second quarter worth approximately $28,000. Finally, Lynx Investment Advisory purchased a new position in Novartis in the 2nd quarter valued at $29,000. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.